Permanently Discontinued

XULTOPHY

NOVO NORDISK CANADA INC

This is a national manufacturer shortage report. It does not confirm whether the product is unavailable at your local pharmacy — call ahead or ask your pharmacist.

Quick answers

Is XULTOPHY discontinued in Canada?

Yes. The manufacturer has reported to Health Canada that XULTOPHY 3.6MG 100UNIT has been permanently discontinued (last updated January 14, 2026). It is not expected to come back, so talk to your pharmacist or doctor about an alternative.

Why is XULTOPHY not available?

The reason the manufacturer reported: Business reasons.

Can I still get this?Check with your pharmacist

StatusPermanently Discontinued

Same-ingredient products on fileNone found

Affected strength3.6MG 100UNIT

Last updated2026-01-14

What this means

Does this mean I need to switch medications right away?

Not necessarily right away, but this product will not be returning to the market.

What should I do?

Talk to your pharmacist or prescriber about your options well before your current supply runs out.

DIN

02474875

Strength

3.6MG 100UNIT

Dosage Form

SOLUTION

Route

SUBCUTANEOUS

Active Ingredient

LIRAGLUTIDE INSULIN DEGLUDEC

Compare with another product →

Product Monograph

Official Product Monograph (Health Canada)

View official Health Canada drug record ↗

Shortage History

2026-01-14

Permanently Discontinued

Business reasons

Other Products from NOVO NORDISK CANADA INC

Other Health Canada-approved products made by the same manufacturer — not necessarily related to this shortage, and not necessarily in shortage themselves.

ACTIVELLE

DIN 02249405

ACTIVELLE LD

DIN 02309009

AWIQLI

2100UNIT · DIN 02546221

AWIQLI

700UNIT · DIN 02546205

AWIQLI

1050UNIT · DIN 02546213

ESPEROCT

500UNIT · DIN 02490064